Please assess the completion status of the following clinical trial:

Trial Title: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria~* Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy (the wash-out period will be at least 1 month)~* Patients who are not eligible for resection and are chemotherapy naïve~* Patients with HER2(-) status~* Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT guidance~* Patients must have adequate organ function~* Patients must provide written informed consent~Exclusion Criteria:~* Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years~* ECOG performance status worse than 2~* Prior oral or intravenous chemotherapy for metastatic disease~* Patients with comorbidities that prevent them from being able to receive the chemotherapy regimen~* cardiac ejection fraction 45% or greater

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).